TCTR20220112004招募中不适用
Safety and Immunogenicity of adenovirus vector COVID-19 vaccines following with additional dose of mRNA COVID-19 vaccines for cancer patients.
Quality Improvement fund, King chulalongkorn Memorial Hospital,The Thai Red Cross Society0 个研究点目标入组 400 人开始时间: 2022年1月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •1)Patients age 18 years old and older
- •2)Diagnosed with cancer and is undergoing treatment at Chulalongkorn Hospital
- •3)ECOG Performance status 0-2
- •4)Has given consent to receiving COVID-19 vaccine
- •5)Has given consent to participate in the research study
排除标准
- •1)Has histories of allergies (especially allergic reactions to vaccines)
- •2)Has histories of immune deficiency diseases (e.g. HIV or congenital immune deficiency)
- •3)Has been infected with COVID-19 within 14 days before receiving the vaccine
- •4)Has fever higher than 38c within 24 hours before receiving the vaccine
- •5)Received COVID-19 vaccine before
- •6)Has histories of hematologic diseases or has limitations for intramuscular injections
- •7)Has received immunosuppressant drugs unrelated to their cancer treatment
研究者
相似试验
招募中
不适用
Safety and Immunogenicity of adenovirus vector COVID-19 vaccines for radiotherapy patients in ThailandWhat are the immunization and safety effects of the COVID-19 adenovirus vector Astrazenaca vaccine in irradiated patients in Thailand?radiation, covid-19, vaccineTCTR20210921002King Chulalongkorn Memorial Hospital120
进行中（未招募）
不适用
Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster DoseHepatitis AEUCTR2015-005191-18-Outside-EU/EEASanofi Pasteur SA720
尚未招募
1 期
CENTAURO-6 StudyLiver NeoplasmsCarcinoma, HepatocellularDigestive System NeoplasmsLiver DiseasesDigestive System DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialHepatocellular carcinomaRPCEC00000237Center for Genetic Engineering and Biotechnology (CIGB), in Havana.20
Unknown
3 期
Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older.COVID-19PACTR20201152310190334,520
已完成
不适用
Safety and efficacy of cidofovir for adenovirus infectioadenovirus infectionJPRN-UMIN000004336Hematology, Osaka City University, Graduate School of Meicine21